{"id":252333,"date":"2023-06-15T00:00:00","date_gmt":"2023-06-15T00:00:00","guid":{"rendered":"https:\/\/clarivate.com\/products\/research-reports\/report\/epidim0041-biopharma-atopic-dermatitis-atopic-eczema-epidemiology\/"},"modified":"2026-05-11T23:24:11","modified_gmt":"2026-05-11T23:24:11","slug":"epidim0041-biopharma-atopic-dermatitis-atopic-eczema-epidemiology-mature-markets","status":"publish","type":"report","link":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/epidim0041-biopharma-atopic-dermatitis-atopic-eczema-epidemiology-mature-markets\/","title":{"rendered":"Atopic Dermatitis \/ Atopic Eczema &#8211; Epidemiology &#8211; Mature Markets"},"content":{"rendered":"<p>Clarivate Epidemiology\u2019s coverage of atopic dermatitis\/atopic eczema (<abbr title=\"atopic dermatitis\">AD<\/abbr>) comprises epidemiological estimates of key patient populations in the major mature pharmaceutical markets (the United States, France, Germany, Italy, Spain, the United Kingdom, and Japan). We report the prevalence of <abbr title=\"atopic dermatitis\">AD<\/abbr> for each country, as well as annualized case counts projected to the national population.<\/p>\n<p>Most patient populations are forecast over a period of 20 years for the major mature pharmaceutical markets and 10 years for the other countries covered in this report. In addition to forecasting prevalent patient populations, we estimate the number of drug-treatment opportunities in specific lines of therapy in the major mature pharmaceutical markets.<\/p>\n<p>Clarivate Epidemiology\u2019s <abbr title=\"atopic dermatitis\">AD<\/abbr> forecast will answer the following questions:<\/p>\n<ul class=\"round-bullets\">\n<li>Of all people with <abbr title=\"atopic dermatitis\">AD<\/abbr>, how many in each of the major mature pharmaceutical markets have been formally diagnosed?<\/li>\n<li>Of all people diagnosed with <abbr title=\"atopic dermatitis\">AD<\/abbr>, how many in each of the major mature pharmaceutical markets are drug-treated?<\/li>\n<li>How will demographic trends, such as population aging and improving life expectancy, affect the epidemiology of <abbr title=\"atopic dermatitis\">AD<\/abbr> over the forecast period?<\/li>\n<\/ul>\n<p>All forecast data are available on the Clarivate Insights Platform in tabular format, with options to download to MS Excel. All populations are accompanied by a comprehensive description of the methods and data sources used, with hyperlinks to external sources. A summary evidence table generated as part of our systematic review of the epidemiological literature is also provided for full transparency into research and methods.<\/p>\n<p>Clarivate Epidemiology provides at least 20 years of forecast data for the following <abbr title=\"atopic dermatitis\">AD<\/abbr> populations:<\/p>\n<ul class=\"round-bullets\">\n<li>Total 12-month prevalent cases of <abbr title=\"atopic dermatitis\">AD<\/abbr>.<\/li>\n<li>Total 12-month prevalent cases of <abbr title=\"atopic dermatitis\">AD<\/abbr> by severity.<\/li>\n<li>Diagnosed 12-month prevalent cases of <abbr title=\"atopic dermatitis\">AD<\/abbr>.<\/li>\n<li>Diagnosed 12-month prevalent cases of <abbr title=\"atopic dermatitis\">AD<\/abbr> by severity.<\/li>\n<li>Diagnosed 12-month prevalent cases of <abbr title=\"atopic dermatitis\">AD<\/abbr> by treatment status.<\/li>\n<\/ul>\n<p>Note: Coverage may vary by country.<\/p>\n","protected":false},"template":"","class_list":["post-252333","report","type-report","status-publish","hentry","report-gateway-biopharma","biopharma-product-epidemiology","biopharma-date-975"],"acf":[],"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"_links":{"self":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/252333","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report"}],"about":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/types\/report"}],"version-history":[{"count":2,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/252333\/revisions"}],"predecessor-version":[{"id":305354,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/252333\/revisions\/305354"}],"wp:attachment":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/media?parent=252333"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}